Asset Dedication LLC Has $60,000 Holdings in Sanofi (NASDAQ:SNY)

Asset Dedication LLC decreased its position in Sanofi (NASDAQ:SNYFree Report) by 68.0% in the fourth quarter, HoldingsChannel reports. The firm owned 1,248 shares of the company’s stock after selling 2,654 shares during the period. Asset Dedication LLC’s holdings in Sanofi were worth $60,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in SNY. Charles Schwab Investment Management Inc. raised its holdings in shares of Sanofi by 31.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 139,505 shares of the company’s stock worth $8,040,000 after acquiring an additional 33,105 shares in the last quarter. Arkadios Wealth Advisors lifted its stake in Sanofi by 19.0% in the fourth quarter. Arkadios Wealth Advisors now owns 4,709 shares of the company’s stock valued at $227,000 after acquiring an additional 751 shares during the last quarter. Geode Capital Management LLC grew its position in Sanofi by 7.1% in the third quarter. Geode Capital Management LLC now owns 254,738 shares of the company’s stock worth $14,681,000 after acquiring an additional 16,780 shares in the last quarter. JPMorgan Chase & Co. increased its stake in shares of Sanofi by 20.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock worth $133,172,000 after purchasing an additional 399,301 shares during the last quarter. Finally, GFS Advisors LLC raised its holdings in shares of Sanofi by 1,017.9% during the 3rd quarter. GFS Advisors LLC now owns 12,800 shares of the company’s stock valued at $738,000 after purchasing an additional 11,655 shares in the last quarter. 14.04% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. StockNews.com cut shares of Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday. Two equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $60.00.

Get Our Latest Research Report on Sanofi

Sanofi Stock Performance

NASDAQ:SNY opened at $54.15 on Friday. The firm has a market capitalization of $137.42 billion, a PE ratio of 27.63, a PEG ratio of 1.19 and a beta of 0.57. Sanofi has a 1 year low of $45.22 and a 1 year high of $58.97. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The firm’s fifty day simple moving average is $49.12 and its 200 day simple moving average is $52.24.

Sanofi (NASDAQ:SNYGet Free Report) last issued its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.70. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. On average, sell-side analysts anticipate that Sanofi will post 3.82 EPS for the current year.

Sanofi Profile

(Free Report)

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

Further Reading

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNYFree Report).

Institutional Ownership by Quarter for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.